Recovery & Repair Peptides | Tissue Repair Research Compounds
Recovery and repair peptides work across multiple biological pathways — angiogenesis, fibroblast activation, actin cytoskeleton dynamics, immune modulation, and nitric oxide signalling — to support tissue repair research across tendon, muscle, GI, skin, and wound healing models. All compounds are supplied in-house at ≥99% purity.
5
Tissue repair research compounds
NO/VEGF
BPC-157 primary pathways
Actin
TB-500 primary mechanism
≥99%
HPLC purity — all compounds
Research Compounds in This Category
QSC supplies five repair and recovery research peptides with complementary, non-overlapping mechanisms:
Why BPC-157 + TB-500 combination is mechanistically justified
BPC-157 and TB-500 are frequently researched together because their molecular targets do not overlap. BPC-157 activates NO synthase and upregulates VEGF/EGF; TB-500 sequesters G-actin enabling cell migration and activates NF-κB anti-inflammatory signalling. The combination addresses multiple independent repair pathways simultaneously — which is why QSC offers a pre-blended 10mg:10mg vial for controlled ratio consistency across subjects.
BPC-157 (Body Protection Compound-157) is a synthetic 15-amino acid peptide derived from a protective gastric protein. Research applications include tendon and ligament repair models (via tenocyte stimulation and VEGF-mediated angiogenesis), GI mucosal repair and cytoprotection, nitric oxide synthase (NOS) pathway studies, and wound healing models. It is studied in rodent models of tendon transection, GI ulceration, anastomosis healing, and nerve repair.
What is the difference between BPC-157 and TB-500?
BPC-157 and TB-500 (Thymosin Beta-4 fragment) work through non-overlapping molecular targets that converge on tissue repair. BPC-157 primarily activates NO synthase, upregulates VEGF and EGF, and directly stimulates tenocytes. TB-500 sequesters G-actin (enabling cell migration), activates an independent angiogenesis pathway, and has strong NF-κB-mediated anti-inflammatory effects. Their mechanisms are complementary — not redundant — which is the scientific rationale for combined protocols.
Can BPC-157 and TB-500 be combined in research?
Yes. The mechanistic rationale for BPC-157 + TB-500 combination is well-supported: the two peptides work through independent molecular targets (NO synthase vs actin sequestration; VEGF/EGF vs NF-κB anti-inflammatory; tenocyte stimulation vs cell migration). QSC supplies a pre-blended 10mg:10mg BPC-157 + TB-500 vial for researchers requiring a consistent ratio across subjects in combination protocols.
Does QSC ship recovery peptides domestically?
Yes. BPC-157, TB-500, GHK-Cu, Thymosin Alpha-1, and all recovery category compounds ship from domestic QSC warehouses in USA, EU, UK, Canada, and Australia.
QSC quality standard — every compound, every batch
≥99% Purity
HPLC verified — full chromatogram in COA
MS Identity
Molecular weight confirmed every batch
Janoshik COA
Independent third-party — publicly verifiable
Direct Manufacture
Fmoc SPPS in-house — Qingdao facility
5-Region Shipping
Domestic: USA · EU · UK · Canada · Australia
Research Use Only: All products sold on qsc-eu.com are intended strictly for laboratory research purposes only. They are not approved for human consumption, veterinary use, or any other application.
